Genmab A/S (GMAB)
Stock Price:
$37.13 USD
1.22 (3.40%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $35.10 -2.03 (-5.47%) Nov 27, 4:26 PM
Key Info
| Market Cap |
24.29B |
| Revenue (ttm) |
800.90M |
| Net Income (ttm) |
323.28M |
| Shares Out |
654.10M |
| EPS (ttm) |
0.51 |
| PE Ratio |
72.80 |
| Forward PE |
49.75 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$37.13 |
| Previous Close |
$35.91 |
| Change ($) |
1.22 |
| Change (%) |
3.40% |
| Day's Open |
36.76 |
| Day's Range |
36.69 - 37.29 |
| Day's Volume |
171,318 |
| 52-Week Range |
24.13 - 39.81 |
More Stats
| Market Cap |
24.29B |
| Enterprise Value |
22.68B |
| Earnings Date (est) |
Feb 24, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
654.10M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
0.51 |
| FCF / Share |
0.28 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
1.37% |
| FCF Yield |
0.75% |
| Payout Ratio |
n/a |
| Shares Short |
1.33M |
| Short Ratio |
1.53 |
| Short % of Float |
n/a |
| Beta |
0.58 |
| PE Ratio |
72.80 |
| Forward PE |
49.75 |
| P/FCF Ratio |
133.93 |
| PS Ratio |
30.32 |
| PB Ratio |
8.15 |
| Revenue |
800.90M |
| Operating Income |
393.73M |
| Net Income |
323.28M |
| Free Cash Flow |
181.34M |
| Net Cash |
1.61B |
| Net Cash / Share |
2.46 |
| Gross Margin |
100.00% |
| Operating Margin |
49.16% |
| Profit Margin |
40.40% |
| FCF Margin |
22.64% |
| ROA |
27.27% |
| ROE |
36.46% |
| ROIC |
33.00% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (25)
| Buy |
12 |
| Overweight |
2 |
| Hold |
8 |
| Underweight |
1 |
| Sell |
2 |
Analyst Consensus: Overweight
Price Target
$38.14*
(2.72% upside)
Low
24.0
Current: $37.13
High
44.4
Target: 38.14
*Average 12-month USD price target from 22 stock analysts.
Financial Performance
Financial numbers in millions DKK.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 5,366 | 3,025 | 2,365 |
| Revenue Growth | 77.39% | 27.91% | - |
| Gross Profit | 5,366 | 3,025 | 2,365 |
| Operating Income | 2,638 | 1,380 | 1,344 |
| Net Income | 2,166 | 1,472 | 1,104 |
| Shares Outstanding | 64.30 | 64.30 | - |
| Earnings Per Share | 3.40 | 2.37 | 1.78 |
| EPS Growth | 43.4% | 33.54% | - |
| Operating Cash Flow | 1,326 | 1,015 | 1,589 |
| Capital Expenditures | -111 | -478 | -89.00 |
| Free Cash Flow | 1,215 | 537 | 1,500 |
| Cash & Equivalents | 10,971 | 6,106 | 5,423 |
| Total Debt | 181 | - | - |
| Net Cash / Debt | 10,790 | 6,106 | 5,423 |
| Assets | 15,144 | 8,461 | 6,603 |
| Liabilities | 1,096 | 447 | 331 |
| Book Value | 14,048 | 8,014 | 6,272 |
Numbers in millions DKK, except per-share numbers.
Company Details
| Full Name |
Genmab A/S |
| Country |
Denmark |
| Employees |
712 |
| CEO |
Jan G. J. van de Winkel |
Stock Information
| Ticker Symbol |
GMAB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GMAB |
Description
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.